UNLABELLED: Serum adiponectin (ADP) levels are reported inversely related to the risk in breast, endometrial cancer, and gastric cancer. Serum ADP as a potential marker compared with CA-19-9 in pancreatic carcinoma (PC) and chronic pancreatitis (CP) was studied. Adiponectin and CA-19-9 levels were examined at the time of diagnosis in patients with CP and PC. METHODS: Serum ADP and CA-19-9 levels were measured by immunoassays in 72 patients with PC and 39 with CP and 290 control subjects. RESULTS: The median levels of ADP for PC were significantly higher than those for CP and control subjects (P = 0.0035). Increasing the upper reference value of ADP allowed for better discrimination between CP and PC. The introduction of 28 ng/mL as a cutoff for ADP significantly improved its specificity. At an elevated cutoff level for ADP (28 ng/mL), a better discrimination between PC and CP was obtained. CONCLUSIONS: Adiponectin might be useful in the differential diagnosis of PC and CP with elevated CA-19-9. This gives rise to the possibility that ADP has a potential role in differentiating CP and PC.
UNLABELLED: Serum adiponectin (ADP) levels are reported inversely related to the risk in breast, endometrial cancer, and gastric cancer. Serum ADP as a potential marker compared with CA-19-9 in pancreatic carcinoma (PC) and chronic pancreatitis (CP) was studied. Adiponectin and CA-19-9 levels were examined at the time of diagnosis in patients with CP and PC. METHODS: Serum ADP and CA-19-9 levels were measured by immunoassays in 72 patients with PC and 39 with CP and 290 control subjects. RESULTS: The median levels of ADP for PC were significantly higher than those for CP and control subjects (P = 0.0035). Increasing the upper reference value of ADP allowed for better discrimination between CP and PC. The introduction of 28 ng/mL as a cutoff for ADP significantly improved its specificity. At an elevated cutoff level for ADP (28 ng/mL), a better discrimination between PC and CP was obtained. CONCLUSIONS:Adiponectin might be useful in the differential diagnosis of PC and CP with elevated CA-19-9. This gives rise to the possibility that ADP has a potential role in differentiating CP and PC.
Authors: Rachael Z Stolzenberg-Solomon; Stephanie Weinstein; Michael Pollak; Yuzhen Tao; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: Am J Epidemiol Date: 2008-09-18 Impact factor: 4.897
Authors: Ying Bao; Edward L Giovannucci; Peter Kraft; Meir J Stampfer; Shuji Ogino; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; John Michael Gaziano; Nader Rifai; Michael N Pollak; Barbara B Cochrane; Virginia Kaklamani; Jennifer H Lin; Joann E Manson; Charles S Fuchs; Brian M Wolpin Journal: J Natl Cancer Inst Date: 2012-12-14 Impact factor: 13.506
Authors: Maria Dalamaga; Ilias Migdalis; Jessica L Fargnoli; Evangelia Papadavid; Erica Bloom; Nicholas Mitsiades; Konstantinos Karmaniolas; Nicolaos Pelecanos; Sofia Tseleni-Balafouta; Amalia Dionyssiou-Asteriou; Christos S Mantzoros Journal: Cancer Causes Control Date: 2008-12-03 Impact factor: 2.506
Authors: Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill Journal: Curr Mol Med Date: 2013-03 Impact factor: 2.222